ALS Longitude Prize
Longitude Prize on ALS (Amyotrophic Lateral Sclerosis)
The Longitude Prize on ALS is a global initiative to incentivise the use of AI to transform drug discovery for the treatment of ALS (also known as MND or motor neuron disease), launching in 2025.
The Prize will engage disease experts and data scientists worldwide to identify and validate drug targets and pathways relevant to disease progression, driving understanding of the disease and supporting onward translation into drug discovery.
The Prize is convening global data partners to bring a unique data offer to prize participants, giving access to data at an unprecedented scale.
The Prize will raise awareness of ALS as a disease ready for and in need of solutions.
Are you:
- An ALS researcher with an interest in drug discovery?
- A computational biologist working in neurodegeneration?
- A scientist in a techbio with an interesting AI model?
What is ALS?
ALS (amyotrophic lateral sclerosis), the most common form of motor neuron disease (MND), is a progressive neurodegenerative disease that is currently incurable, with an average life expectancy post-diagnosis of just two to four years. Although often described as a rare disease, incidence is not uncommon: there is a 1 in 300 chance that a person develops MND in their lifetime. Current treatment for sporadic forms of ALS (up to 85% of those diagnosed) is restricted to one approved therapy and supportive care.
The Longitude Prize is an innovative approach which has the potential to be transformative for motor neuron disease research. We are investing as the principal funder, confident that the Prize will bring exciting new technologies and create unique collaborations, to accelerate the search for effective treatments for this brutal disease.